Investigations to the influence of tumor supressor gene p16 inactivation on the prognosis of head and neck squamous cell carcinoma;Untersuchungen zum einfluss der inaktivierung des tumorsupressorgenes p16 auf die prognose von plattenepithelkarzinomen der kopf-hals-region

Laryngo- Rhino- Otologie

Volumn 83, Issue 6, 2004, Pages 374-380

  Koscielny, Sven ^a   Eggeling, F V ^a   Dahse, R ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b Institut für Pathologie   (Germany)

Author keywords

Head and neck cancer; Inactivation of p16; LOH; Methylation of promoter region; Tumor prognosis

Indexed keywords

GENE PRODUCT; PROTEIN P16;

ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; GENE INACTIVATION; HEAD AND NECK CARCINOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARYNX CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METHYLATION; MOUTH CARCINOMA; PHARYNX CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC NEOPLASMS; POINT MUTATION; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES; RISK ASSESSMENT; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS;

EID: 3042669596     PISSN: 09358943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-814359     Document Type: Article

References (41)

1. Serrano M, Hannon GJ, Beach D. A new regulatory modify in cell-cycle control causing specific inhibition of cyclin d/CKD 4. Nature 1993; 366: 704-707
2. Lundblad V. The end replication problem: more than one solution. Nat Med 1997; 3: 1198-1189
3. Loughran O, Edington KD, Berry IJL, Clark J, Parkinson LJ. Loss of hetero-zygosity of chromosome 9p21 is asssociated with the immortal phenotype of neoplastic human head and neck keratinocytes. Cancer Res 1994; 54: 5045-5049
4. Riet P, Nawroz H, Hruban RH, Tokino K, Koch W, Sidransky D. Frequent loss of chromosome 9p21-22 early in the head and neck cancer progression. Cancer Res 1994; 54: 1156-1158
5. Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res 1997; 237: 7-13
6. Maelandsmo GM, Florenes VA, Hovig E, Oyjord T, Engelbraaten O, Holm R, Borresen AL, Fodstad O. Involvement of the pRb/p16/cdk4/Cyclin D1 pathway in the tumorgenesis of sporadic melanomas. Br J Cancer 1996; 73: 909-916
7. Rusin MR, Okamoto A, Chorazy K, Czyzewski K, Harasim J, Spilare EA, Hagiwara K, Hussain SP, Xiong Y, Demetrick DJ, Harris CC. Intragenic mutations of the p16 INK 4, p 15 INK 4 B and p 18 genes in primary non-small-cell lung cancers. Int J Cancer 1996; 65: 734-739
8. Huang L, Goodrow L, Zhang SY, Klein-Szanto AJP, Chang H, Ruggert BA. Deletion and mutation analyses of the p16/MTS 1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res 1996; 56: 1137-1141
9. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000; 60: 892-895
10. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA. Methylation of the 5 CpG island of the p16/CDKN tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995; 55: 4531-4535
11. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/cdkn2/mts1 in human cancers. Nat Med 1995; 1: 686-692
12. Cairns P, Li M, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, Riet P, Blaugrund JA, Sidransky D. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994; 265: 415-416
13. Kamb A, Liu Q, Harshman K, Tatigion S, Cordon-Cardo C, Skolnick MH. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994; 265: 415-417
14. Reed JA, Loganzo F, Shea CR, Walker GJ, Flores JF, Glendning JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995; 55: 2713-2718
15. Zhao Y, Zhang S, Fu B, Xiao C. Abnormalities of tumor suppressor genes P16 and P15 in primary maxillofacial squamous cell carcinomas. Cancer Genet Cytogenet 1999; 112: 26-33
16. Cody DT, Huang Y, Darby CJ, Johnson GK, Domann FE. Differential DNA methylation of the p16 INK4A/CDKN2A promoter in human oral cancer cells and normal human oral keratinocytes. Oral Oncol 1999; 35: 516-522
17. El-Naggar AK, Lai S, Clayman G, Lee JK, Luna MA, Goepfert H, Batsakis JG. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol 1997; 151: 1767-1774
18. Mori T, Miura K, Aoki K, Nishihira A, Mori S, Nakamura Y. Frequent somatic mutation of the MTS1/CDK 41 Gene in Esophageal squamous cell carcinoma. Cancer Res 1994; 54: 3396-3397
19. Sato K, Schäuble B, Kleihues P, Ogaki H. Infrequent alterations of the p15, p16, CDK 4 and Cyclin D 1 genes in non-astrocytic human brain tumors. Int J Cancer 1996; 65: 305-308
20. Gonzalez MV, Pello MF, Lopez-Larrea C, Suarez C, Menendez MJ, Coto E. Deletion and methylation of the tumour suppressor gene p16/CDKN2 in primary head and neck squamous cell carcinoma. J Clin Pathol 1997; 50: 509-512
21. Bova RJ, Quinn DI, Nankervis JS, Cole IE, Sheridan BF, Jensen MJ, Morgan GJ, Hughes CJ, Sutherland RL. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999; 5: 2810-2819
22. Danahey DG, Tobin EJ, Schuller DE, Bier-Laning CM, Weghorst CM, Lang JC. p16 mutation frequency and clinical correlation in head and neck cancer. Acta Otolaryngol 1999; 119: 285-288
23. Koscielny S, Fiedler W, Beleites E, Claussen U. Welche Rolle spielt die Inaktivierung des Promotors p16 bei der Entstehung eines Kopf-Hals-Karzinoms? HNO 1999; 47: 396
24. Riese U, Dahse R, Fiedler W, Koscielny S, There C, Ernst G, Beleites E, Claussen U, Eggeling F. Tumor suppresser gene p 16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer. Int J Molecul Med 1999; 3: 61-65
25. Dai S, Huang W, Gan X. The expression of p16, Rb and Cyclin D1 and biological behaviour of laryngeal cancer. Chung Hua Erh Pi Yen Hou Ko Tsa Chih 1997; 32: 299-301
26. Gulley ML, Nicholls JM, Schneider BG, Amin MB, Ro JY, Geradts J. Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. Am J Pathol 1998; 152: 865-869
27. Shibosawa E, Tsutsumi K, Koizuka I, Hoshikawa M, Takakuwa T. Absence of nuclear p16 from Epstein-Barr virus-associated undifferentiated nasopharyngeal carcinomas. Laryngoscope 2000; 110: 93-97
28. Lydiatt WM, Davidson BJ, Schantz SP, Caruana S, Chaganti RS. 9p21 deletion correlates with recurrence in head and neck cancer. Head Neck 1998; 20: 113-118
29. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D. A novel p16INK4A transcript. Cancer Res 1995; 55: 2995-2997
30. Miracca EC, Kowalski LP, Nagai MA. High prevalence of p16 genetic alterations in head and neck tumours. Br J Cancer 1999; 81: 677-683
31. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, Rollins BJ. Reciprocal Rb inactivation and p16 INK4 expression in primary lung cancers and cell lines. Cancer Res 1995; 55: 505-509
32. Faderl S, Estrov Z, Kantarjian HM, Thomas D, Cortes J, Manshouri T, Chan CC, Hays KJ, Pierce S, Albitar M. The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukaemia. Cytokines Cell Mol Ther 1999; 5: 159-163
33. Guo SX, Taki T, Ohnishi H, Piao HY, Tabuchi K, Bessho F, Hanada R, Yanagisawa M, Hayashi Y. Hypermethylation of p16 and p15 genes and RB protein expression in acute leukaemia. Leuk Res 2000; 24: 39-46
34. Woodcock DM, Linsenmeyer ME, Doherty JP, Warren WD. DNA methylation in the promoter region of the p16 (CDKN2/MTS-1/INK4A) gene in human breast tumours. Br J Cancer 1999; 79: 251-256
35. Musgrove EA, Lilischkis R, Cornish AL, Lee CSL, Setlur V, Seshadri R, Sutherlland RL. Expression of the cyclin-depend kinase inhibitors p16 INK4, p15 INK4B and p21 WAF1/CIPI in human breast cancer. Int J Cancer 1995; 63: 584-591
36. Jares P, Nadal A, Fernandez PL, Pinyol M, Hernandez L, Cazorla M, Hernandez S, Bea S, Cardesa A, Campo E. Disregulation of p16MTS1/CDK41 protein and mRNA expression is associated with gene alterations in squamous-cell carcinoma of the larynx. Int J Cancer 1999; 81: 705-711
37. Kyritsis AP, Zhang B, Zhang W, Xio M, Takeshima H, Bondy ML, Cunningham JE, Levin VA, Bruner J. Mutations of the p16 gene in gliomas. Oncogen 1995; 11: 63-67
38. Luca M, Xie S, Gutman M, Huang S, Bar-Eli M. Abnormalities in the CDKN 2 (p16 INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis. Oncogene 1995; 11: 1399-140
39. Skollnick MH, Cannon-Albright LA, Kamb A. Genetic predisposition to melanoma. Eur J Cancer 1994; 30: 1991-1995
40. Yuan J, Knorr J, Altmannsberger M, Goeckenjan G, Ahr A, Scharl A, Strebhardt K. Expression of p16 and lack of pRB in primary small cell lung cancer. J Pathol 1999; 189: 358-362
41. Takeuchi H, Ozawa S, Ando N, Shih CH, Koyanagi K, Ueda M, Kitajima M. Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin Cancer Res 1997; 3: 2229-2236